Schwab International Equity ETF
SCHWAB STRATEGIC TRUST · Series S000026637 · 1 share classes
data updated 2026-09-08
Fund profile
As filed in the prospectus · 2025 Q4
The funds goal is to track as closely as possible, before fees and expenses, the total return of the FTSE Developed ex US Index.
The fund tracks the FTSE Developed ex US Index, which comprises large and mid-cap stocks across 24 developed markets outside the United States, using sampling techniques to hold a subset of index constituents expected to replicate index performance. Because the fund samples rather than holds all index securities, its returns may diverge from the index. The fund may invest up to 10% of assets in securities not in the index, including those anticipated to be added or needed to reflect corporate actions, and may use futures and other derivatives to optimize cash deployment and tracking.
| Share class | Expense ratio |
|---|---|
| SCHF | 0.03% |
Portfolio turnover 4.00% · as of 2025 Q4
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.32% |
| Cash & short-term | 0.52% |
| Derivatives | 0.01% |
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
Largest new: Roche Holding AG, SUNB, Toromont Industries Ltd, Thomson Reuters Corp, IAMGOLD Corp, First Majestic Silver Corp, Equinox Gold Corp, Wise Group PLC
Largest exited: Roche Holding AG, Ashtead Group PLC, Thomson Reuters Corp, Wise PLC, ICE Futures U.S., Inc., Swissquote Group Holding SA, Telecom Italia SpA/Milano, JDE Peet's NV
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | Samsung Electronics Co Ltd | 3.32% | $210.35 | $2.21B | 10.5M |
| — | SK hynix Inc | 2.81% | $1,548.11 | $1.87B | 1.2M |
| — | ASML Holding NV | 2.10% | $1,615.99 | $1.40B | 864.4K |
| — | HSBC Holdings PLC | 1.08% | $18.79 | $719.28M | 38.3M |
| — | Roche Holding AG | 0.99% | $421.45 | $659.83M | 1.6M |
| — | Novartis AG | 0.97% | $150.79 | $645.99M | 4.3M |
| — | AstraZeneca PLC | 0.93% | $186.04 | $621.26M | 3.3M |
| RY | Royal Bank of CanadaRY | 0.90% | $191.96 | $598.61M | 3.1M |
| — | Nestle SA | 0.88% | $101.67 | $583.65M | 5.7M |
| — | Shell PLC | 0.80% | $42.03 | $533.26M | 12.7M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
Top 10 positions are 14.79% of net assets, top 25 24.10%, across 1.4K issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free